Crinetics Pharmaceuticals Management
Management criteria checks 3/4
Crinetics Pharmaceuticals' CEO is R. Struthers, appointed in Dec 2008, has a tenure of 15.92 years. total yearly compensation is $5.75M, comprised of 10.7% salary and 89.3% bonuses, including company stock and options. directly owns 1.1% of the company’s shares, worth $57.26M. The average tenure of the management team and the board of directors is 3.3 years and 4.2 years respectively.
Key information
R. Struthers
Chief executive officer
US$5.7m
Total compensation
| CEO salary percentage | 10.7% |
| CEO tenure | 15.9yrs |
| CEO ownership | 1.1% |
| Management average tenure | 3.3yrs |
| Board average tenure | 4.2yrs |
Recent management updates
Recent updates
We're Hopeful That Crinetics Pharmaceuticals (NASDAQ:CRNX) Will Use Its Cash Wisely
Oct 02
Crinetics Pharmaceuticals: Stop, Look, And Listen Before Buying This High-Priced Clinical Stage Biotech
Aug 12Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation
Jun 01Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data
May 23Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)
Feb 29Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
Nov 28Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?
Aug 08Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
Dec 31Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation
Sep 14Crinetics Pharmaceuticals GAAP EPS of -$0.81 misses by $0.15, revenue of $0.44M misses by $0.28M
Aug 12We're Not Very Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Rate
Jun 15Crinetics: Late-Stage Acromegaly Disease Studies Will Be Major Inflection Point
Jun 13CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$278m |
| Jun 30 2024 | n/a | n/a | -US$259m |
| Mar 31 2024 | n/a | n/a | -US$235m |
| Dec 31 2023 | US$6m | US$614k | -US$215m |
| Sep 30 2023 | n/a | n/a | -US$199m |
| Jun 30 2023 | n/a | n/a | -US$184m |
| Mar 31 2023 | n/a | n/a | -US$175m |
| Dec 31 2022 | US$6m | US$590k | -US$164m |
| Sep 30 2022 | n/a | n/a | -US$150m |
| Jun 30 2022 | n/a | n/a | -US$136m |
| Mar 31 2022 | n/a | n/a | -US$119m |
| Dec 31 2021 | US$4m | US$567k | -US$108m |
| Sep 30 2021 | n/a | n/a | -US$98m |
| Jun 30 2021 | n/a | n/a | -US$89m |
| Mar 31 2021 | n/a | n/a | -US$79m |
| Dec 31 2020 | US$4m | US$544k | -US$74m |
| Sep 30 2020 | n/a | n/a | -US$67m |
| Jun 30 2020 | n/a | n/a | -US$63m |
| Mar 31 2020 | n/a | n/a | -US$59m |
| Dec 31 2019 | US$4m | US$542k | -US$50m |
| Sep 30 2019 | n/a | n/a | -US$44m |
| Jun 30 2019 | n/a | n/a | -US$38m |
| Mar 31 2019 | n/a | n/a | -US$31m |
| Dec 31 2018 | US$3m | US$410k | -US$27m |
| Sep 30 2018 | n/a | n/a | -US$21m |
| Jun 30 2018 | n/a | n/a | -US$16m |
| Mar 31 2018 | n/a | n/a | -US$12m |
| Dec 31 2017 | US$385k | US$350k | -US$9m |
Compensation vs Market: R.'s total compensation ($USD5.75M) is about average for companies of similar size in the US market ($USD7.78M).
Compensation vs Earnings: R.'s compensation has increased whilst the company is unprofitable.
CEO
R. Struthers (61 yo)
15.9yrs
Tenure
US$5,747,994
Compensation
Dr. R. Scott Struthers, Ph.D. founded Crinetics Pharmaceuticals, Inc. in November 2008 and serves as its Chief Executive Officer and President since December 2008. He is Chairman at Radionetics Oncology, I...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 15.9yrs | US$5.75m | 1.1% $ 57.3m | |
| Founder & Chief Scientific Officer | 3.1yrs | US$2.50m | 0.021% $ 1.1m | |
| Chief Financial Officer | 6.8yrs | US$2.51m | 0.062% $ 3.2m | |
| Chief Operating Officer | 3.2yrs | US$2.36m | 0.0044% $ 227.2k | |
| Chief Endocrinologist | 6.4yrs | US$2.16m | 0.014% $ 729.9k | |
| Head of Investor Relations | no data | no data | no data | |
| General Counsel & Corporate Secretary | 3.4yrs | no data | no data | |
| Chief Human Resources Officer | 4.5yrs | no data | no data | |
| Head of Intellectual Property | no data | no data | no data | |
| Chief Business Officer | 2.7yrs | no data | no data | |
| Chief Medical & Development Officer | 2.2yrs | US$3.61m | 0.0023% $ 119.6k | |
| Senior Vice President of Medical Affairs | less than a year | no data | no data |
3.3yrs
Average Tenure
59.5yo
Average Age
Experienced Management: CRNX's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 16yrs | US$5.75m | 1.1% $ 57.3m | |
| Independent Chairman of the Board | 9.1yrs | US$375.31k | 0.11% $ 5.9m | |
| Independent Director | 6.8yrs | US$348.56k | 0.020% $ 1.0m | |
| Independent Director | 4.2yrs | US$339.56k | 0.0065% $ 336.4k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2.8yrs | US$338.56k | 0.012% $ 616.6k | |
| Independent Director | 6.8yrs | US$338.56k | 0.0065% $ 336.4k | |
| Independent Director | 5.3yrs | US$342.31k | 0.0065% $ 336.4k | |
| Independent Director | 2.7yrs | US$330.06k | 0.0065% $ 336.4k | |
| Member of Scientific Advisory Board | 2.6yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.6yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.6yrs | no data | no data |
4.2yrs
Average Tenure
61yo
Average Age
Experienced Board: CRNX's board of directors are considered experienced (4.2 years average tenure).